DV
Dividend Vision

DERM — Journey Medical Corp

Journey Medical Corp (DERM)

Total return is -32.1% over the past 4.8 years, 109.3 points behind SPY at 77.2%. Its deepest 1-year drawdown was 52.6%.

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing dermatological products in the United States, with marketed offerings including Qbrexza for hyperhidrosis, Accutane for severe acne, Amzeeq and Zilxi for acne and rosacea, and several other topical and oral treatments for various skin conditions. The company does not currently distribute to shareholders. This stock appeals to investors seeking exposure to specialty pharmaceutical development rather than current income generation.

DERM key facts

Asset type
Stock
Asset class
Equity
Inception date
11/12/2021
Last close
$6.72
Market cap
$197,147,360
Average volume
281638.0
Beta
1.073
Payout ratio
0.0
Forward P/E
212.766
EPS
$-0.37